Company Profiles

driven by the PitchBook Platform

Accium BioSciences

Description

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

2004

Founded

PRIVATE

Status

11-50

Employees

Conv. Debt

Latest Deal Type

$250k

Latest Deal Amount

$3.61M

Total Amount Raised

Description

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

Website:

www.acciumbio.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Other Pharmaceuticals and Biotechnology

Other Industries

Social/Platform Software

Primary Office

550 17th Avenue Suite 550 Seattle, WA 98122United States +1 (206) 258-8860
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Accium BioSciences's full profile, request a free trial.

    Accium BioSciences Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Accium BioSciences Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Accium BioSciences Investors (3)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Alliance of AngelsAngel GroupMinority000 0000000 0000
    SabeyCorporate Venture CapitalMinority000 0000000 0000
    WRF CapitalVenture CapitalMinority000 0000000 0000
    Alliance of Angels Angel Group
    Sabey Corporate Venture Capital
    WRF Capital Venture Capital

    Accium BioSciences Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Jonathan AdlerStudy Director
    Glenn Kawasaki Ph.DChief Executive Officer & President
    Barbara Alford-CasselVice President, Quality Assurance & Quality Assurance Officer
    Jonathan Adler Study Director
    Glenn Kawasaki Ph.D Chief Executive Officer & President
    Barbara Alford-Cassel Vice President, Quality Assurance & Quality Assurance Officer
    Request full access to PitchBook